Health risk assessment of pesticides residue in maize and cowpea from Ejura, Ghana.

Low productivity in agriculture due to damage cause by pests has led to the application of pesticides to control pest infestation. Residues of pesticides applied on crops are often found in the food which can cause chronic effect on the health of humans who consume such products. The aim of this study is to measure pesticides residues in maize and cowpea and compare the values with stablished safety limits. A total of 37 pesticides comprising 15 organochlorines, 13 organophosphorus and 9 pyrethroids pesticides were identified in maize and cowpea samples obtained from farms in Ejura. Analytical methods included solvent extraction of the pesticide residues and their subsequent quantification using gas chromatograph equipped with Electron Capture Detector and Pulse Flame Photometric Detector after clean-up on alumina/activated charcoal column. The results showed that the mean concentration of pesticides in maize ranged from 0.001 to 0.103 mg kg(-1) for organochlorine pesticides, 0.002-0.019 mg kg(-1) for organophosphorus pesticides and 0.002-0.028 mg kg(-1) for pyrethroids pesticides. In cowpea the mean concentration ranged from 0.001 to 0.108 mg kg(-1) for organochlorine pesticides, 0.002-0.015 mg kg(-1) for organophosphorus pesticides and 0.001-0.039 mg kg(-1) for pyrethroids pesticides. Maximum Residue Limits for ß-HCH, ß-endosulfan, p,p'-DDE and p,p'-DDD were exceeded in both maize and cowpea samples. Health risk estimation revealed that residues of heptachlor, dieldrin, endrin, ß-endosulfna, γ-chlordane and chlorfenvinphos found in maize exceeded the Acceptable Daily Intake. Similarly the levels of heptachlor and p,p'-DDD found in cowpea also exceeded the Acceptable Daily Intake. This suggests a great potential for chronic toxicity to consumers of these food items.

Simple and efficient ion imprinted polymer for recovery of uranium from environmental samples.

Ion imprinted polymer material (IIP) was prepared by forming ternary complexes of uranyl imprint ion with 1-(prop-2-en-1-yl)-4-(pyridin-2-ylmethyl)piperazine and methacrylic acid followed by thermal copolymerization with ethylene glycol dimethacrylate as the cross-linking monomer in the presence of 1,1'-azobis(cyclohexanecarbonitrile) initiator and 2-methoxy ethanol porogenic solvent. HCl solution (5 mol/L) was used to leach out the uranyl template ion from the IIP particles. Similarly, the control polymer (CP) material was also prepared exactly under the same conditions as the IIP but without the uranyl ion template. Various parameters such as solution pH, initial concentration, aqueous phase volume, sorbent dosage, contact time and leaching solution volumes were investigated. SEM, IR and BET-surface area and pore size analysis were used for the characterization of IIP and CP materials. The extraction efficiency of the IIP and CP was compared using a batch and SPE mode of extraction. The optimal pH for quantitative removal is 4.0-8.0, sorbent amount is 20 mg, contact time is 20 min and the retention capacity is 120 mg of uranyl ion per g of IIP. The IIP prepared demonstrated superior selectivity towards coexisting cations and therefore it can be used for selective removal of uranium from complex matrices.

Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy.

The objective of this study was to assess the efficacy and safety of amitriptyline as a treatment of FM. A comprehensive computerized search in Medline (Pubmed), EMBASE and The Cochrane Library was performed. Randomized controlled trials (RCTs) comparing amitriptyline vs placebo in adult patients suffering from FM were identified, the methodological quality was assessed and the results of the main outcomes were evaluated. Ten RCTs were identified. Large clinical variability and statistical heterogeneity precluded quantitative meta-analysis. Overall, the study quality was moderate to high. Amitriptyline 25 mg/day (six RCTs) demonstrated a therapeutic response compared with placebo in the domains of pain, sleep, fatigue and overall patient and investigator impression. This benefit was generally seen at 6-8 weeks of treatment but no effect was noted at 12 weeks. Amitriptyline 50 mg/day (four RCTs) did not demonstrate a therapeutic effect compared with placebo. Neither dose of amitriptyline had an effect on tender points count. No clear statements on adverse events with amitriptyline can be made due to inconsistencies in data among the studies. A definitive clinical recommendation regarding the efficacy of amitriptyline for FM symptoms cannot be made. There is some evidence to support the short-term efficacy of amitriptyline 25 mg/day in FM. There is no evidence to support the efficacy of amitriptyline at higher doses or for periods >8 weeks. More stringent RCTs with longer follow-up periods are required to determine the long-term efficacy and safety of the amitriptyline and define its role in the multidisciplinary management of FM.